• Kripto Paralar
  • Tahmin Piyasaları
  • Haberler
  • Ajansal İşlem
  • Yazılar
  • Ligler

Kripto Paraları Ara

Trend Kripto Paralar

CoinRithm

Şirket

Tüzel Kişilik
Bees-x Limited
Şirket Numarası
13308136
Kuruluş Yeri
England and Wales
Kayıtlı Ofis
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm, Bees-x Limited tarafından işletilen bir bilgi ve araştırma hizmetidir. Düzenlenmiş faaliyetleri yürütmek üzere Financial Conduct Authority (FCA) tarafından yetkilendirilmemiştir ve bu sitedeki hiçbir içerik finansal tavsiye değildir.

Keşfet

Kripto ParalarTahmin PiyasalarıHaberlerYazılarAgent ArenaLigler

Özellikler

Kontrol PaneliTicaret SimülasyonuAjansal İşlemPortföyİzleme ListesiAyarlar

Şirket

HakkımızdaMetodolojiKullanım ŞartlarıGizlilik PolitikasıÇerez PolitikasıFeragatname

Destek

Destekle İletişimSSSGeliştirici kitiMCP belgeleri

Sosyal Medya

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tüm hakları saklıdır.
Google Play'de edininApp Store'dan İndirin
  • Ana Sayfa
  • PiyasalarTahmin Piyasaları
  • Haberler
  • Kontrol Paneli
  1. Tahmin Piyasaları
  2. Health & Medicine
  3. What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold Markets

What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?

Health & MedicineOne-Off2ay
Manifold MarketsManifold MarketsKYC yok
Güncel topluluk tahmini
Manifold Markets
20-29% 9.4%
7 seçenek arasında lider
Tahminciler

11

Soru türü

multiple choice

Yöntem

Play-money forecasting platform

Kaynak türü

Tahmin

Piyasa verileri

evvelsi gün guncellendi

Guncelligini yitirmis
15 Mar 24 21:292 Eyl 26 6:59

Trendler

Sonuç24sOlasılık

Seçilen sonuç

20-29%9%

Kurallar

The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.

Manifold Markets
  • Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
  • Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
  • Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
  • 1Day Sooner has an R21 Status Report available here that may be useful.
  • More malaria-related questions can be found on our Manifold account here.

İlgili Piyasalar

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

₺7,9 Mn
Evet: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

₺886,8 B
Evet: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

₺468,1 B
Evet: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

₺67 B
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

₺24,7 B
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

₺7,3 B
2025: 0%Manifold MarketsMANIFOLD MARKETS

Bu konularda aktif

BitcoinBTC$62,767.61+1.84%EthereumETH$1,656.56+1.23%SolanaSOL$65.16+1.43%DogecoinDOGE$0.085+1.18%XRPXRP$1.12+0.40%BNBBNB$598.88+2.03%

İlgili Haberler

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Kurallar

The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.

Manifold Markets
  • Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
  • Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
  • Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
  • 1Day Sooner has an R21 Status Report available here that may be useful.
  • More malaria-related questions can be found on our Manifold account here.